Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 4,728 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,728 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $146.41, for a total transaction of $692,226.48. Following the sale, the chief executive officer now owns 185,034 shares in the company, valued at $27,090,827.94. The trade was a 2.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $468,111.60.
• On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The shares were sold at an average price of $120.76, for a total value of $206,378.84.
• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52.

Natera Stock Down 3.3 %

Shares of Natera stock opened at $146.06 on Friday. The stock has a market capitalization of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.01 and a current ratio of 4.39. The company has a 50-day simple moving average of $127.38 and a two-hundred day simple moving average of $115.46. Natera, Inc. has a 52-week low of $52.01 and a 52-week high of $167.79.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the prior year, the business earned ($0.95) EPS. The business’s revenue for the quarter was up 63.9% compared to the same quarter last year. On average, analysts anticipate that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on NTRA shares. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 price target on shares of Natera in a research note on Friday, September 13th. Craig Hallum boosted their price target on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday. Canaccord Genuity Group lifted their price objective on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday. BTIG Research upped their price objective on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, The Goldman Sachs Group increased their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $137.65.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Natera by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after acquiring an additional 72,848 shares during the period. Farallon Capital Management LLC increased its holdings in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after buying an additional 1,883,481 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after acquiring an additional 85,236 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Natera by 7.4% during the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after purchasing an additional 143,825 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.